EGFR and non-small cell lung carcinoma: There is, however, ample real‐world research on first/second‐generation EGFR‐TKI use in the first‐line treatment of patients with EGFRm+ advanced NSCLC, and these reports have identified factors negatively affecting PFS.11, 12, 13